Solivan Leah
Known title: DirectorCIK: 0002028705
Associated companies
Transaction History
| PETS | ▲ Buy | Grant | 33,846 | $0 | 10/30/2025 | View on chart |
| PETS | ▲ Buy | Grant | 7,500 | $0 | 8/8/2024 | View on chart |
| PETS | ▲ Buy | Grant | 943 | $0 | 7/1/2024 | View on chart |
| PETS | ▲ Buy | Grant | 33,846 | $0 | 10/30/2025 | View on chart |
| PETS | ▲ Buy | Grant | 7,500 | $0 | 8/8/2024 | View on chart |
| PETS | ▲ Buy | Grant | 943 | $0 | 7/1/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Morgan Stanley Lowers PETS Target to $1.40
Morgan Stanley has kept its underweight view on PETS but cut its price target to $1.40. The rating signals the firm expects the stock to trade below its current level. With the RSI near 19, the shares are in oversold territory and near a support level of $1.96. This downgrade may influence investor sentiment.
Morgan Stanley Lowers PETS Target to $1.40. Morgan Stanley has kept its underweight view on PETS but cut its price target to $1.40. The rating signals the firm expects the stock to trade below its current level. With the RSI near 19, the shares are in oversold territory and near a support level of $1.96. This downgrade may influence investor sentiment.